NCT00079820View on ClinicalTrials.gov

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Smallpox
Interventions
BIOLOGICAL

ACAM3000 MVA Vaccine

Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days

Trial Locations (2)

66219

PRA International, Lenexa

40536-0093

University of Kentucky Medical Center, Lexington

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00079820 - Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults | Biotech Hunter | Biotech Hunter